Form 4: Ocular Therapeutix Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Ocular Therapeutix's Executive Chairman, President, and CEO, Pravin Dugel, sold 20,680 shares of common stock to cover tax obligations related to vesting restricted stock units.
Summary
- Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, Inc., sold 20,680 shares of common stock on November 25, 2024.
- The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units on November 22, 2024.
- The shares were sold at a weighted average price of $9.01, with individual transactions ranging from $8.88 to $9.11.
- The sale was not a discretionary trade but rather part of a pre-arranged automatic sale instruction adopted on February 21, 2024.
- Following the transaction, Mr. Dugel directly owns 791,793 shares of Ocular Therapeutix common stock.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction for tax purposes, not indicative of any positive or negative sentiment towards the company's performance.
Management Comments
- The sales do not represent a discretionary trade by the reporting person.
Industry Context
This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.
Comparison to Industry Standards
- The sale of shares to cover tax obligations is a standard practice among executives in publicly traded companies.
- Many companies use restricted stock units as part of their compensation packages, and executives often sell a portion of these shares upon vesting to cover taxes.
- The price range of $8.88 to $9.11 is within the normal trading range for Ocular Therapeutix stock.
Stakeholder Impact
- The sale of shares by an executive may have a minor impact on the stock price, but this transaction is not expected to have a significant impact on shareholders.
Key Dates
| Date | Description |
|---|---|
| 2024-02-21 | Date the reporting person adopted a durable automatic sale instruction. |
| 2024-11-22 | Date of vesting of restricted stock units that triggered the tax obligations. |
| 2024-11-25 | Date of the stock sale. |
| 2024-11-27 | Date of the filing of the Form 4. |
Keywords
Ocular Therapeutix, Pravin Dugel, stock sale, insider trading, tax obligations, restricted stock units, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.